Klaas Mulder


The epidermal layer of human skin is continuously replenished by resident stem cells while differentiated cells are shed from the surface. Disrupting this balance of stem cell renewal
and differentiation contributes to diseases, such as psoriasis and cancer. Therefore, the
mechanisms governing epidermal stem cell fate decisions must be robust, precise and tightly controlled.

The Mulder lab investigates the mechanisms underlying human epidermal stem cell renewal
& differentiation focusing on the epigenetic and non-coding RNA machineries. We are
particularly interested in understanding how the functional interplay between seemingly
unconnected genes and cellular processes confers robustness and precision to biological

The approaches we use to address these questions include: molecular biology, cell biology,
primary human epidermal (organotypic) culture, genomics, proteomics,  siRNA/CRISPR-based genetic screening technologies, as well as novel computational

Moreover, our lab is actively developing new technologies to open avenues towards new biological questions and insights. We recently described the ‘Immuno-Detection by Sequencing’ (ID-seq) technology that allows us to quantify >80 (phospho-)proteins in hundreds of samples in a single experiment (van Buggenum, Nature Communications 2018).
We have recently extended the ID-seq approach to measure 70 (phospho-)proteins in single cells (van Eijl, iScience 2018), as well as combine RNA and intracellular protein measurements from the same individual cell (RAID: Gerlach, Scientific Reports 2019).

We are now applying these new technologies to understand the connections between signalling pathway activity and transcriptional output at the single cell level in healthy and disease contexts.


Klaas Mulder obtained his PhD from the University of Utrecht (NL) in 2006 working on transcription regulation in yeast. During a post-doctoral period in the lab of Prof. Fiona Watt in Cambridge (UK) he studied the role of epigenetic factors in human epidermal stem cell differentiation. Klaas arrived at the RIMLS in September 2012 to head his independent research group.


2018 ALW-OPEN grant, NWO
2018 Unique High Risk grant, Dutch Cancer Society
2013 VIDI Grant, Innovational Research Initiative Scheme, NWO
2013 Marie Curie Career Integration Grant
2012 Radboud University Nijmegen FWNI Fellowship
2008 Marie Curie Intra-European Fellowship
2007 Rubicon Fellowship, NWO
2003 European Molecular Biology Organisation (EMBO) short-term fellowship